| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus | 31 | 2025 | 94 | 7.600 |
Why?
|
| Cytomegalovirus Infections | 17 | 2025 | 68 | 3.980 |
Why?
|
| Viral Proteins | 14 | 2022 | 270 | 1.750 |
Why?
|
| Virus Replication | 11 | 2018 | 323 | 1.600 |
Why?
|
| E2F1 Transcription Factor | 10 | 2011 | 18 | 1.470 |
Why?
|
| Genetic Variation | 7 | 2019 | 394 | 1.450 |
Why?
|
| DNA Damage | 11 | 2014 | 297 | 1.350 |
Why?
|
| DNA-Binding Proteins | 17 | 2013 | 1225 | 1.310 |
Why?
|
| Cell Cycle Proteins | 13 | 2011 | 402 | 1.230 |
Why?
|
| Immediate-Early Proteins | 8 | 2012 | 46 | 1.080 |
Why?
|
| Genome, Viral | 6 | 2020 | 144 | 0.880 |
Why?
|
| Apoptosis | 12 | 2010 | 1098 | 0.880 |
Why?
|
| Evolution, Molecular | 10 | 2020 | 350 | 0.790 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2022 | 86 | 0.770 |
Why?
|
| Selection, Genetic | 5 | 2020 | 90 | 0.740 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2012 | 210 | 0.720 |
Why?
|
| Trans-Activators | 6 | 2012 | 321 | 0.720 |
Why?
|
| Cell Cycle | 10 | 2008 | 398 | 0.720 |
Why?
|
| Drug Resistance, Viral | 7 | 2022 | 160 | 0.710 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2006 | 318 | 0.700 |
Why?
|
| Nuclear Proteins | 8 | 2012 | 790 | 0.670 |
Why?
|
| Epithelial Cells | 2 | 2021 | 413 | 0.620 |
Why?
|
| Superinfection | 1 | 2019 | 12 | 0.620 |
Why?
|
| Genetic Engineering | 1 | 2021 | 113 | 0.610 |
Why?
|
| Fibroblasts | 12 | 2020 | 422 | 0.610 |
Why?
|
| Transcription Factors | 10 | 2012 | 1556 | 0.590 |
Why?
|
| Oseltamivir | 6 | 2022 | 35 | 0.580 |
Why?
|
| Viral Tropism | 1 | 2019 | 55 | 0.560 |
Why?
|
| Multiprotein Complexes | 1 | 2019 | 156 | 0.530 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 2013 | 49 | 0.530 |
Why?
|
| Signal Transduction | 10 | 2019 | 3153 | 0.510 |
Why?
|
| Cell Line | 18 | 2020 | 2024 | 0.490 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2025 | 80 | 0.440 |
Why?
|
| Mutation | 14 | 2022 | 2661 | 0.430 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 4 | 2019 | 44 | 0.430 |
Why?
|
| Neuraminidase | 4 | 2022 | 43 | 0.430 |
Why?
|
| Humans | 55 | 2025 | 65140 | 0.420 |
Why?
|
| Antiviral Agents | 7 | 2023 | 321 | 0.420 |
Why?
|
| G1 Phase | 6 | 2008 | 58 | 0.420 |
Why?
|
| RNA Interference | 4 | 2019 | 643 | 0.410 |
Why?
|
| Viruses | 3 | 2023 | 81 | 0.400 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 59 | 0.400 |
Why?
|
| DNA Repair | 4 | 2014 | 262 | 0.380 |
Why?
|
| RNA, Small Interfering | 8 | 2019 | 981 | 0.380 |
Why?
|
| Influenza A virus | 4 | 2022 | 119 | 0.380 |
Why?
|
| Macaca mulatta | 5 | 2025 | 260 | 0.370 |
Why?
|
| Host-Pathogen Interactions | 2 | 2016 | 279 | 0.360 |
Why?
|
| Retinoblastoma Protein | 5 | 2004 | 45 | 0.360 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2012 | 17 | 0.360 |
Why?
|
| DNA, Viral | 7 | 2017 | 231 | 0.350 |
Why?
|
| Glioma | 1 | 2012 | 101 | 0.340 |
Why?
|
| Viral Envelope Proteins | 3 | 2021 | 101 | 0.340 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 30 | 0.340 |
Why?
|
| Virus Diseases | 2 | 2023 | 117 | 0.330 |
Why?
|
| Polymorphism, Genetic | 4 | 2021 | 198 | 0.330 |
Why?
|
| Membrane Glycoproteins | 3 | 2024 | 662 | 0.320 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 5 | 2013 | 43 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2010 | 205 | 0.310 |
Why?
|
| Genes, Viral | 7 | 2017 | 57 | 0.300 |
Why?
|
| Recombination, Genetic | 4 | 2019 | 256 | 0.290 |
Why?
|
| Infant, Newborn | 6 | 2023 | 1422 | 0.280 |
Why?
|
| Gene Expression Regulation | 7 | 2016 | 1630 | 0.270 |
Why?
|
| Sequence Analysis, DNA | 6 | 2017 | 414 | 0.260 |
Why?
|
| Carrier Proteins | 6 | 1998 | 718 | 0.260 |
Why?
|
| Genetics, Population | 3 | 2017 | 45 | 0.260 |
Why?
|
| Pyrazines | 2 | 2017 | 35 | 0.250 |
Why?
|
| Animals | 31 | 2025 | 21345 | 0.250 |
Why?
|
| Amides | 2 | 2017 | 60 | 0.250 |
Why?
|
| Bluetongue virus | 3 | 1991 | 3 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2006 | 113 | 0.240 |
Why?
|
| Genes, Retinoblastoma | 1 | 2006 | 5 | 0.240 |
Why?
|
| Biological Evolution | 3 | 2017 | 128 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 70 | 0.220 |
Why?
|
| Phylogeny | 6 | 2020 | 388 | 0.220 |
Why?
|
| Molecular Sequence Data | 15 | 2014 | 1979 | 0.220 |
Why?
|
| Vagus Nerve | 1 | 2024 | 20 | 0.220 |
Why?
|
| Models, Genetic | 4 | 2020 | 266 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2006 | 583 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 178 | 0.220 |
Why?
|
| Immunoglobulins | 1 | 2024 | 74 | 0.220 |
Why?
|
| Biological Specimen Banks | 1 | 2024 | 23 | 0.210 |
Why?
|
| Specimen Handling | 1 | 2024 | 61 | 0.210 |
Why?
|
| Transforming Growth Factor beta | 2 | 2002 | 181 | 0.200 |
Why?
|
| Antigens, CD | 1 | 2024 | 342 | 0.200 |
Why?
|
| Dogs | 7 | 2019 | 315 | 0.200 |
Why?
|
| Immunoblotting | 3 | 2013 | 202 | 0.190 |
Why?
|
| Virology | 1 | 2023 | 13 | 0.190 |
Why?
|
| Base Sequence | 14 | 2006 | 1332 | 0.190 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 465 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2013 | 233 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 217 | 0.190 |
Why?
|
| Genomics | 2 | 2016 | 384 | 0.190 |
Why?
|
| Viral Matrix Proteins | 3 | 2014 | 50 | 0.180 |
Why?
|
| Genetic Drift | 3 | 2020 | 15 | 0.180 |
Why?
|
| Antibodies, Viral | 3 | 2021 | 325 | 0.180 |
Why?
|
| E2F Transcription Factors | 7 | 2004 | 16 | 0.180 |
Why?
|
| Down-Regulation | 4 | 2012 | 324 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 85 | 0.180 |
Why?
|
| Influenza, Human | 4 | 2022 | 203 | 0.180 |
Why?
|
| Genetic Testing | 2 | 2021 | 141 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2008 | 713 | 0.180 |
Why?
|
| Transfection | 7 | 2013 | 700 | 0.170 |
Why?
|
| Microglia | 1 | 2024 | 250 | 0.170 |
Why?
|
| Research | 1 | 2023 | 194 | 0.170 |
Why?
|
| Infant | 3 | 2017 | 1693 | 0.170 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 80 | 0.160 |
Why?
|
| Viremia | 1 | 2020 | 46 | 0.160 |
Why?
|
| Genetic Fitness | 2 | 2018 | 35 | 0.160 |
Why?
|
| HeLa Cells | 2 | 2019 | 541 | 0.160 |
Why?
|
| Reoviridae | 2 | 1990 | 2 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2002 | 341 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 6 | 1997 | 687 | 0.160 |
Why?
|
| Mutation Rate | 2 | 2017 | 24 | 0.160 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2017 | 60 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 104 | 0.150 |
Why?
|
| HEK293 Cells | 2 | 2019 | 616 | 0.150 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 100 | 0.150 |
Why?
|
| Capsid | 2 | 1991 | 104 | 0.150 |
Why?
|
| Capsid Proteins | 2 | 1991 | 107 | 0.150 |
Why?
|
| Haplotypes | 1 | 2019 | 134 | 0.150 |
Why?
|
| RNA, Double-Stranded | 2 | 1990 | 112 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 2 | 2021 | 369 | 0.150 |
Why?
|
| Transcriptional Activation | 4 | 1997 | 197 | 0.150 |
Why?
|
| A549 Cells | 1 | 2019 | 39 | 0.150 |
Why?
|
| Cells, Cultured | 8 | 2006 | 2188 | 0.150 |
Why?
|
| Organ Preservation | 1 | 2019 | 22 | 0.140 |
Why?
|
| Perfusion | 1 | 2019 | 75 | 0.140 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2019 | 94 | 0.140 |
Why?
|
| Enzyme Inhibitors | 3 | 2016 | 367 | 0.140 |
Why?
|
| Reperfusion Injury | 1 | 2019 | 57 | 0.140 |
Why?
|
| Silent Mutation | 1 | 2018 | 5 | 0.140 |
Why?
|
| S Phase | 5 | 2002 | 79 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 34 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 215 | 0.130 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 59 | 0.130 |
Why?
|
| Cluster Analysis | 2 | 2015 | 261 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 765 | 0.130 |
Why?
|
| Pandemics | 4 | 2023 | 674 | 0.130 |
Why?
|
| Madin Darby Canine Kidney Cells | 4 | 2019 | 21 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 312 | 0.130 |
Why?
|
| Brain | 2 | 2024 | 1605 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2006 | 58 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2019 | 219 | 0.120 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2016 | 11 | 0.120 |
Why?
|
| Cloning, Molecular | 7 | 2017 | 385 | 0.120 |
Why?
|
| Gene Editing | 1 | 2021 | 328 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 76 | 0.120 |
Why?
|
| I-kappa B Proteins | 2 | 1993 | 37 | 0.120 |
Why?
|
| Lentivirus | 1 | 2016 | 64 | 0.120 |
Why?
|
| Zika Virus | 1 | 2016 | 37 | 0.120 |
Why?
|
| Pregnancy | 4 | 2025 | 2372 | 0.120 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2016 | 62 | 0.120 |
Why?
|
| Adenoviridae | 5 | 2001 | 130 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2009 | 78 | 0.120 |
Why?
|
| Dengue Virus | 1 | 2016 | 99 | 0.120 |
Why?
|
| AIDS Vaccines | 1 | 2016 | 72 | 0.120 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2016 | 84 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 250 | 0.110 |
Why?
|
| NF-kappa B | 3 | 1995 | 435 | 0.110 |
Why?
|
| Sequence Alignment | 2 | 2017 | 300 | 0.110 |
Why?
|
| Reassortant Viruses | 1 | 2015 | 10 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 235 | 0.110 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2014 | 13 | 0.110 |
Why?
|
| Protein Binding | 7 | 2017 | 1640 | 0.110 |
Why?
|
| Endometrium | 1 | 1994 | 31 | 0.100 |
Why?
|
| Placenta | 2 | 2025 | 69 | 0.100 |
Why?
|
| Oropharynx | 1 | 2014 | 12 | 0.100 |
Why?
|
| Genes, Immediate-Early | 1 | 2013 | 8 | 0.100 |
Why?
|
| Glycoproteins | 1 | 2015 | 189 | 0.100 |
Why?
|
| Female | 11 | 2025 | 34018 | 0.100 |
Why?
|
| Models, Molecular | 4 | 2019 | 1162 | 0.100 |
Why?
|
| Islets of Langerhans | 2 | 2005 | 286 | 0.100 |
Why?
|
| Demography | 1 | 2013 | 178 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 211 | 0.100 |
Why?
|
| Amino Acid Sequence | 7 | 2017 | 1589 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2014 | 105 | 0.090 |
Why?
|
| DNA | 2 | 1995 | 858 | 0.090 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2012 | 14 | 0.090 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1993 | 119 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2014 | 199 | 0.090 |
Why?
|
| Gene Expression | 3 | 2017 | 852 | 0.090 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 242 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2012 | 72 | 0.090 |
Why?
|
| Eukaryotic Cells | 2 | 2002 | 57 | 0.090 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 563 | 0.090 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 27 | 0.090 |
Why?
|
| Phosphorylation | 6 | 2006 | 962 | 0.090 |
Why?
|
| Mice | 11 | 2010 | 11119 | 0.080 |
Why?
|
| Caffeine | 1 | 2011 | 46 | 0.080 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 5 | 1998 | 6 | 0.080 |
Why?
|
| Autophagy | 2 | 2010 | 237 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 509 | 0.080 |
Why?
|
| Models, Biological | 5 | 2004 | 1192 | 0.080 |
Why?
|
| Iodide Peroxidase | 2 | 2000 | 23 | 0.080 |
Why?
|
| Rats | 5 | 2002 | 1994 | 0.080 |
Why?
|
| Rhadinovirus | 2 | 2009 | 4 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2002 | 33 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2017 | 122 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2002 | 53 | 0.080 |
Why?
|
| Gammaherpesvirinae | 1 | 2009 | 4 | 0.080 |
Why?
|
| Transcription Factor DP1 | 4 | 1998 | 4 | 0.080 |
Why?
|
| Diploidy | 1 | 2008 | 11 | 0.070 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2006 | 28 | 0.070 |
Why?
|
| Histones | 1 | 2011 | 494 | 0.070 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2017 | 86 | 0.060 |
Why?
|
| Open Reading Frames | 2 | 2020 | 84 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2012 | 2061 | 0.060 |
Why?
|
| Virus Latency | 1 | 2006 | 31 | 0.060 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2006 | 6 | 0.060 |
Why?
|
| MRE11 Homologue Protein | 1 | 2006 | 8 | 0.060 |
Why?
|
| Binding Sites | 3 | 2017 | 921 | 0.060 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2006 | 15 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2006 | 17 | 0.060 |
Why?
|
| Interferon Regulatory Factors | 1 | 2006 | 43 | 0.060 |
Why?
|
| DNA Repair Enzymes | 1 | 2006 | 38 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 2293 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 180 | 0.060 |
Why?
|
| Cell Survival | 1 | 2006 | 587 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1038 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2006 | 224 | 0.050 |
Why?
|
| Point-of-Care Testing | 1 | 2024 | 40 | 0.050 |
Why?
|
| E2F2 Transcription Factor | 1 | 2004 | 2 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2004 | 7 | 0.050 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2004 | 11 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2024 | 117 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 1222 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2005 | 179 | 0.050 |
Why?
|
| Protein Structure, Secondary | 2 | 2017 | 260 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 345 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2016 | 500 | 0.050 |
Why?
|
| Hydrogen Bonding | 2 | 2016 | 128 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2000 | 611 | 0.050 |
Why?
|
| Male | 5 | 2024 | 31047 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2002 | 17 | 0.050 |
Why?
|
| Genes, APC | 1 | 2002 | 12 | 0.050 |
Why?
|
| Cell Division | 2 | 2002 | 450 | 0.050 |
Why?
|
| E2F4 Transcription Factor | 1 | 2002 | 2 | 0.050 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 13 | 0.050 |
Why?
|
| Policy Making | 1 | 2023 | 48 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2005 | 433 | 0.050 |
Why?
|
| Aged | 2 | 2024 | 14965 | 0.050 |
Why?
|
| Smad3 Protein | 1 | 2002 | 17 | 0.050 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 710 | 0.050 |
Why?
|
| Antigens, Viral | 3 | 1992 | 130 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 162 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 2001 | 27 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2023 | 113 | 0.040 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2020 | 19 | 0.040 |
Why?
|
| Extinction, Biological | 1 | 2020 | 9 | 0.040 |
Why?
|
| Myosin Type V | 1 | 2000 | 13 | 0.040 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2000 | 22 | 0.040 |
Why?
|
| DNA, Recombinant | 1 | 2020 | 47 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 1290 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 170 | 0.040 |
Why?
|
| Beclin-1 | 2 | 2010 | 22 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 133 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2000 | 81 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 339 | 0.040 |
Why?
|
| Alleles | 2 | 2017 | 453 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 158 | 0.040 |
Why?
|
| Endocytosis | 1 | 2000 | 152 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 152 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 6 | 0.040 |
Why?
|
| Reverse Genetics | 1 | 2019 | 10 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2019 | 125 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2000 | 663 | 0.040 |
Why?
|
| Gamma Rays | 2 | 1995 | 32 | 0.040 |
Why?
|
| RNA Folding | 1 | 2018 | 6 | 0.030 |
Why?
|
| Herpesviridae Infections | 2 | 2009 | 25 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 428 | 0.030 |
Why?
|
| Orthomyxoviridae | 1 | 2017 | 27 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2017 | 102 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 97 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2023 | 827 | 0.030 |
Why?
|
| Adenovirus E1A Proteins | 1 | 1997 | 1 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 238 | 0.030 |
Why?
|
| Transcription, Genetic | 3 | 2002 | 907 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 364 | 0.030 |
Why?
|
| Cyclins | 1 | 1997 | 41 | 0.030 |
Why?
|
| Zanamivir | 1 | 2016 | 5 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 394 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2016 | 102 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 419 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 1993 | 25 | 0.030 |
Why?
|
| Gene Order | 1 | 2016 | 33 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2005 | 868 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 35 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 2016 | 46 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2016 | 251 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 196 | 0.030 |
Why?
|
| Static Electricity | 1 | 2016 | 170 | 0.030 |
Why?
|
| Gene Products, gag | 1 | 2016 | 66 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 134 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 341 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 426 | 0.030 |
Why?
|
| DNA Polymerase II | 1 | 1995 | 8 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 3 | 2002 | 676 | 0.030 |
Why?
|
| Influenza A Virus, H1N2 Subtype | 1 | 2015 | 6 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 168 | 0.030 |
Why?
|
| Nucleoproteins | 1 | 2015 | 32 | 0.030 |
Why?
|
| Interphase | 1 | 1995 | 68 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 25 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2016 | 177 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 49 | 0.030 |
Why?
|
| Oligonucleotide Probes | 2 | 1995 | 41 | 0.030 |
Why?
|
| Genetic Vectors | 3 | 2016 | 918 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1995 | 147 | 0.030 |
Why?
|
| Adult | 1 | 2012 | 17358 | 0.030 |
Why?
|
| Middle Aged | 1 | 2012 | 18273 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 5614 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 1565 | 0.030 |
Why?
|
| Liver | 1 | 2019 | 871 | 0.030 |
Why?
|
| Plasmids | 3 | 2001 | 294 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1994 | 78 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2013 | 15 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 52 | 0.030 |
Why?
|
| Acrosome | 1 | 1993 | 18 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 125 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2016 | 506 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 604 | 0.020 |
Why?
|
| HIV Enhancer | 1 | 1993 | 1 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 171 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 79 | 0.020 |
Why?
|
| Cell Nucleus | 2 | 1995 | 630 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1993 | 513 | 0.020 |
Why?
|
| Antigens | 1 | 1993 | 145 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 673 | 0.020 |
Why?
|
| HIV | 1 | 1993 | 67 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 491 | 0.020 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 1992 | 22 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1993 | 139 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 367 | 0.020 |
Why?
|
| Cyclin A | 2 | 2002 | 8 | 0.020 |
Why?
|
| DNA Replication | 1 | 1994 | 247 | 0.020 |
Why?
|
| Protein Conformation | 2 | 1993 | 792 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1993 | 283 | 0.020 |
Why?
|
| Insulin | 2 | 2005 | 695 | 0.020 |
Why?
|
| United States | 1 | 2024 | 8093 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 3 | 1996 | 11 | 0.020 |
Why?
|
| Sequestosome-1 Protein | 1 | 2010 | 9 | 0.020 |
Why?
|
| Serotyping | 1 | 1990 | 52 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 1995 | 1574 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 99 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 111 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 71 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 105 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 286 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 203 | 0.020 |
Why?
|
| RNA, Viral | 1 | 1991 | 266 | 0.020 |
Why?
|
| Astrocytes | 2 | 2000 | 123 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2002 | 52 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 355 | 0.020 |
Why?
|
| Virulence | 1 | 2009 | 199 | 0.020 |
Why?
|
| Solubility | 1 | 1989 | 192 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1993 | 875 | 0.020 |
Why?
|
| Lysosomes | 1 | 2009 | 173 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 1989 | 243 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2010 | 919 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2000 | 896 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2000 | 152 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 440 | 0.020 |
Why?
|
| Tumor Virus Infections | 1 | 2006 | 26 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 240 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 3762 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 391 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 115 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2006 | 518 | 0.010 |
Why?
|
| Organ Preservation Solutions | 1 | 2005 | 5 | 0.010 |
Why?
|
| Raffinose | 1 | 2005 | 3 | 0.010 |
Why?
|
| Allopurinol | 1 | 2005 | 15 | 0.010 |
Why?
|
| Glutathione | 1 | 2005 | 55 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 220 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 159 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 78 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4809 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 364 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 401 | 0.010 |
Why?
|
| Adenovirus E2 Proteins | 1 | 2002 | 2 | 0.010 |
Why?
|
| Cyclin E | 1 | 2002 | 14 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2002 | 166 | 0.010 |
Why?
|
| beta Catenin | 1 | 2002 | 99 | 0.010 |
Why?
|
| Oncogenes | 1 | 2002 | 70 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 493 | 0.010 |
Why?
|
| Centrosome | 1 | 2002 | 72 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 242 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 2001 | 35 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 44 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 185 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 204 | 0.010 |
Why?
|
| Cisplatin | 1 | 2001 | 145 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 374 | 0.010 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2000 | 2 | 0.010 |
Why?
|
| Affinity Labels | 1 | 2000 | 10 | 0.010 |
Why?
|
| Molecular Motor Proteins | 1 | 2000 | 33 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 2000 | 30 | 0.010 |
Why?
|
| Cell-Free System | 1 | 2000 | 32 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2000 | 77 | 0.010 |
Why?
|
| Thyroxine | 1 | 2000 | 55 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2000 | 165 | 0.010 |
Why?
|
| Actin Cytoskeleton | 1 | 2000 | 78 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2000 | 129 | 0.010 |
Why?
|
| Gene Library | 1 | 2000 | 102 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2000 | 241 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2001 | 198 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 293 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2000 | 144 | 0.010 |
Why?
|
| Endosomes | 1 | 2000 | 180 | 0.010 |
Why?
|
| Actins | 1 | 2000 | 264 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2000 | 372 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2000 | 301 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2000 | 269 | 0.010 |
Why?
|
| Kinetics | 1 | 2000 | 760 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2005 | 839 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2000 | 333 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1997 | 12 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 1996 | 3 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 643 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1996 | 257 | 0.010 |
Why?
|
| Thymidylate Synthase | 1 | 1995 | 6 | 0.010 |
Why?
|
| Ribonucleotide Reductases | 1 | 1995 | 5 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 23 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 1993 | 12 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1993 | 14 | 0.010 |
Why?
|
| TATA Box | 1 | 1993 | 11 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 1993 | 38 | 0.010 |
Why?
|
| Methionine | 1 | 1993 | 57 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1993 | 36 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1993 | 193 | 0.010 |
Why?
|
| DNA Probes | 1 | 1993 | 33 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1993 | 115 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 1993 | 51 | 0.010 |
Why?
|
| Rabbits | 1 | 1993 | 338 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 450 | 0.010 |
Why?
|
| Cricetinae | 1 | 1992 | 362 | 0.010 |
Why?
|
| Lung | 1 | 1993 | 966 | 0.000 |
Why?
|